This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

Dr. Nataliya Uboha explained the benefit of treatment with Krazati combined with Erbitux in KRAS G12C–mutant metastatic colorectal cancer. Among patients with heavily pretreated patients with KRAS ...

Design We conducted a prospective cohort study (NCT04228614) of 171 patients with unresectable metastatic colorectal cancer (mCRC) who underwent first-line treatment and prospectively collected blood ...

Should the primary tumor, if asymptomatic, be resected in patients with colon cancer with synchronous unresectable metastases? Study results hint that the answer is no. FOLFOXIRI plus panitumumab ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...

Palliative care for young adults with colorectal cancer reduced invasive procedures, costs and increased DNR orders. Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in ...

30, 2024 — Metastasis remains the primary challenge ... Scientists Discover How Excessive Red Meat Consumption Increases Colorectal Cancer Risk Oct. 23, 2024 — Scientists have uncovered ...

CheckMate -8HW is a multinational, open-label, randomized trial that enrolled patients with unresectable or metastatic colorectal cancer and MSI-H or dMMR. Participants were randomly assigned in a 2:2 ...

CheckMate -8HW enrolled patients with colorectal cancer whose tumors were characterized as microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic.